title: An indirubin derivative, indirubin-3'-monoxime suppresses oral cancer tumorigenesis through the downregulation of survivin.
abstract: Oral cancer is the fourth most common cause of death from cancer in Taiwanese men. Indirubin-3'-monoxime (I3M), a potent cyclin-dependent kinase inhibitor, has therapeutic effects in other cancer cells. In this study, we carried out in vitro assays to test cell viability, cell cycle progression, apoptosis, cell migration and invasion in this cancer type. In addition, using an oral tumorigenic animal model, we examined target gene and protein expression using real time qPCR, immunoblotting and immunohistochemical staining. Our results demonstrate that I3M has an anti-proliferative effect in both Cal-27 and HSC-3 oral cancer cell lines and that treatment of Cal-27 and HSC-3 cells with I3M results in apoptosis through the activation of cytochrome c. In addition, I3M interrupts the cell cycle in Cal-27 cells in a dose-dependent manner by arresting cells in the G2/M phase. We also found that I3M suppresses migration and invasion in Cal-27 cells by inhibiting the expression of focal adhesion kinase, urokinase-type plasminogen inhibitor, and matrix metalloproteinase 9. Moreover, we identified survivin as a target protein in I3M-treated oral cancer cells. Using an oral cancer mouse model, we demonstrate that topical application of an adhesive gel composed of I3M and poly(vinyl alcohol) (I3M/PVA) has dose-dependent anti-tumorigenic effects. Following treatment, the expression of survivin protein and mRNA was downregulated in cancerous tissues. Furthermore, plasma survivin levels were also reduced in the I3M-treated mice. These results suggest that topical application of I3M, a drug synthesized from indirubin, which is found in Qing-Dai - has therapeutic potential for treating oral cancer.
authors: Graduate Institute Integrated Medicine, China Medical University, Taichung, Taiwan. wylo@mail.cmu.edu.tw
authors: Wan-Yu
authors: WY
authors: Lo
authors: Nai-Wen
authors: NW
authors: Chang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism*; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics / Q000378:metabolism*; D008297:Male; D051379:Mice; D009062:Mouth Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D010091:Oximes / Q000494:pharmacology*; D000077022:Survivin; D047368:Tumor Burden / Q000187:drug effects; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D007211:Indoles; D051034:Inhibitor of Apoptosis Proteins; D010091:Oximes; D000077022:Survivin; D016159:Tumor Suppressor Protein p53; C474021:indirubin-3'-monoxime; D051546:Cyclooxygenase 2
references: Can J Urol. 2008 Apr;15(2):3967-74
references: 18405443
references: Curr Cancer Drug Targets. 2004 Jun;4(4):327-36
references: 15180498
references: Biochem Pharmacol. 2008 May 1;75(9):1729-42
references: 18377873
references: Oral Oncol. 2006 Aug;42(7):655-67
references: 16448841
references: Br J Cancer. 2005 Apr 25;92(8):1341-8
references: 15846296
references: Exp Mol Pathol. 2007 Aug;83(1):131-7
references: 17428462
references: J Biol Chem. 2004 Aug 13;279(33):34087-90
references: 15218035
references: J Biol Chem. 2000 Apr 21;275(16):12266-72
references: 10766865
references: J Cancer Res Clin Oncol. 2004 Nov;130(11):627-35
references: 15340840
references: Cancer Cell. 2010 Jan 19;17(1):53-64
references: 20129247
references: Biochem J. 2003 Apr 1;371(Pt 1):199-204
references: 12534346
references: In Vivo. 2011 May-Jun;25(3):355-66
references: 21576408
references: Med Oncol. 2006;23(3):335-9
references: 17018890
references: J Biol Chem. 2001 May 25;276(21):18563-9
references: 11278747
references: J Biol Chem. 2002 Aug 2;277(31):27982-90
references: 12034711
references: Oncol Rep. 2013 Jan;29(1):371-9
references: 23117445
references: Nature. 1998 Dec 10;396(6711):580-4
references: 9859993
references: Cancer Sci. 2008 Aug;99(8):1507-14
references: 18754860
references: Oncogene. 2007 Sep 27;26(44):6372-85
references: 17533378
references: J Biol Chem. 2001 Jan 5;276(1):251-60
references: 11013232
references: Biochem Biophys Res Commun. 2010 Jan 1;391(1):716-21
references: 19944065
references: Cell Mol Life Sci. 2000 Jan 20;57(1):25-40
references: 10949579
references: Cancer Sci. 2008 Sep;99(9):1709-14
references: 18537980
references: J Oral Pathol Med. 2010 May;39(5):368-75
references: 20050981
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Acta Otolaryngol. 2010;130(1):4-9
references: 19322702
references: Int J Cancer. 2011 Nov 15;129(10):2502-11
references: 21207415
references: Nat Cell Biol. 1999 May;1(1):60-7
references: 10559866
references: Chem Biol Interact. 2010 Jan 5;183(1):231-7
references: 19840781
references: Cancer Lett. 2011 Jul 28;306(2):197-204
references: 21463917
references: Cancer Lett. 2009 Jul 8;279(2):155-62
references: 19251361
references: J Dent Res. 2011 Feb;90(2):168-74
references: 21173435
references: Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):5998-6003
references: 15837920
references: Cell Adh Migr. 2009 Oct-Dec;3(4):347-50
references: 19690467
references: Oral Oncol. 2009 Aug;45(8):647-53
references: 19442563
references: Oral Oncol. 2005 Jul;41(6):645-54
references: 15927524
references: Cancer Sci. 2011 Feb;102(2):324-9
references: 21143701
references: Br J Cancer. 2001 Jan;84(2):283-9
references: 11161389
references: Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Oct;110(4):484-91
references: 20868995
references: EMBO J. 2003 Jun 2;22(11):2729-40
references: 12773388
references: EMBO Rep. 2006 Oct;7(10):988-94
references: 17016456
references: IDrugs. 2008 Mar;11(3):204-14
references: 18311658
references: Nat Rev Mol Cell Biol. 2002 Jun;3(6):401-10
references: 12042762
references: Gynecol Obstet Invest. 2011;71(2):136-40
references: 21160138
references: Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2475-81
references: 20847306
references: Leuk Lymphoma. 2002 Sep;43(9):1763-8
references: 12685829
references: Clin Exp Metastasis. 2004;21(8):737-45
references: 16035618